Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Retained Earnings (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Retained Earnings over the past 3 years, most recently at -$854.7 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$854.7 million for Q4 2025, down 335082.35% from a year ago — trailing twelve months through Dec 2025 was -$854.7 million (down 335082.35% YoY), and the annual figure for FY2025 was -$854.7 million, down 335082.35%.
  • Retained Earnings for Q4 2025 was -$854.7 million at Tonix Pharmaceuticals Holding, down from -$807.8 million in the prior quarter.
  • Over the last five years, Retained Earnings for TNXP hit a ceiling of -$211000.0 in Q1 2023 and a floor of -$854.7 million in Q4 2025.
  • Median Retained Earnings over the past 3 years was -$573.0 million (2023), compared with a mean of -$408.0 million.
  • Biggest five-year swings in Retained Earnings: surged 99.96% in 2024 and later crashed 335082.35% in 2025.
  • Tonix Pharmaceuticals Holding's Retained Earnings stood at -$600.7 million in 2023, then surged by 99.96% to -$255000.0 in 2024, then crashed by 335082.35% to -$854.7 million in 2025.
  • The last three reported values for Retained Earnings were -$854.7 million (Q4 2025), -$807.8 million (Q3 2025), and -$775.8 million (Q2 2025) per Business Quant data.